DERM - Dermira, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
+0.20 (+2.64%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close7.57
Bid6.50 x 1800
Ask8.40 x 900
Day's Range7.61 - 8.08
52 Week Range6.00 - 28.39
Avg. Volume668,713
Market Cap327.279M
Beta (3Y Monthly)1.58
PE Ratio (TTM)N/A
EPS (TTM)-4.91
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.75
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab

    Almirall, S.A. (BME:ALM) and Dermira, Inc. (DERM) announced today that the companies have entered into an option and license agreement under which Almirall has acquired an option to exclusively license rights to develop and commercialize lebrikizumab for the treatment of atopic dermatitis and certain other indications in Europe. In exchange, Dermira will receive an upfront option fee of $30 million.

  • Markit8 days ago

    See what the IHS Markit Score report has to say about Dermira Inc.

    Dermira Inc NASDAQ/NGS:DERMView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on February 5. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding DERM totaled $3.24 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • At biotech's big event, a chance for execs to shape LGBTQ diversity on boards
    American City Business Journalslast month

    At biotech's big event, a chance for execs to shape LGBTQ diversity on boards

    As corporate diversity issues are in the spotlight, a small group will assemble at the J.P. Morgan Healthcare Conference to build a network of current and potential LGBTQ board members.

  • Do Hedge Funds Love Dermira Inc (DERM)?
    Insider Monkey2 months ago

    Do Hedge Funds Love Dermira Inc (DERM)?

    Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in October due to various reasons. Nevertheless, the data show elite investors’ consensus picks have done well on average over the long-term. The top 30 S&P 500 stocks among hedge funds at […]

  • GlobeNewswire2 months ago

    Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that on December 10, 2018, the company granted inducement awards to four new employees. The grants were made pursuant to Dermira’s 2018 Equity Inducement Plan as an inducement material to the employees’ acceptance of employment with Dermira and were approved by the Compensation Committee of Dermira’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4). The company granted restricted stock unit awards (RSUs) representing an aggregate of 2,575 shares of Dermira common stock and stock options to purchase an aggregate of 14,100 shares of Dermira common stock.

  • Is Dermira Inc’s (NASDAQ:DERM) CEO Paid At A Competitive Rate?
    Simply Wall St.2 months ago

    Is Dermira Inc’s (NASDAQ:DERM) CEO Paid At A Competitive Rate?

    Tom Wiggans has been the CEO of Dermira Inc (NASDAQ:DERM) since 2010. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we'll Read More...

  • GlobeNewswire3 months ago

    Report: Exploring Fundamental Drivers Behind CASI Pharmaceuticals, Booking, Enstar Group, Madrigal Pharmaceuticals, Dermira, and Kaiser Aluminum — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire3 months ago

    Dermira to Present at Evercore ISI HealthCONx Conference

    MENLO PARK, Calif., Nov. 19, 2018 -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of DERM earnings conference call or presentation 7-Nov-18 9:30pm GMT

    Q3 2018 Dermira Inc Earnings Call

  • Dermira (DERM) Reports Q3 Loss, Lags Revenue Estimates
    Zacks3 months ago

    Dermira (DERM) Reports Q3 Loss, Lags Revenue Estimates

    Dermira (DERM) delivered earnings and revenue surprises of 20.20% and -10.38%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?